BellaSeno’s resorbable scaffold platform is being developed to support a broad range of soft-tissue applications across multiple clinical indications.
BellaSeno’s bioresorbable breast scaffold is designed to guide the formation of natural tissue using the patient’s own biology. The scaffold provides temporary structure, supporting fat graft integration before gradually resorbing, leaving only native tissue behind.
Developed to support both aesthetic and reconstructive breast procedures, the platform is designed to broaden regenerative pathways across multiple patient needs.
BellaSeno is advancing a clinical program evaluating scaffold-guided soft tissue regeneration, focused on safety, integration, and long-term tissue outcomes. The approach combines bioresorbable scaffolds with autologous fat grafting to support natural tissue formation over time.
The current BRV-005 clinical trial, led by Principal Investigators Prof. Anand Deva and Prof. Owen Ung, is evaluating the technology across both primary augmentation and revision indications, with up to 53 patients enrolled per indication across up to three clinical sites.
Custom-designed scaffolds for chest wall reconstruction support structural restoration in complex defects. Engineered in collaboration with surgeons, these implants provide anatomical fit while guiding tissue integration.
BellaSeno’s resorbable bone scaffolds are designed to stabilise and retain bone graft material in large or complex defects, supporting structured healing and regeneration.
The platform extends beyond breast and bone, with applications across multiple soft tissue indications where structural support and guided regeneration are required.
Deutscher Platz 5A
04103 Leipzig
Germany
4 Starling Street
Burliegh Heads
QLD, Australia, 4220
